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Objectives: To assess rates of informed choice among women offered non‐invasive prenatal
testing (NIPT) for aneuploidy as part of routine clinical care.
Methods: A cross‐sectional survey was conducted across 6 antenatal clinics in England.
Women with a high risk (≥1/150) Down syndrome screening result were offered NIPT, invasive
testing, or no further testing. Pretest counselling was delivered as part of routine care by the local
maternity team. Women were given a questionnaire containing a measure of informed choice
immediately after pretest counselling.
Results: In total, 220 of 247 women completed the questionnaire. Seventy‐six percent were
judged to have made an informed choice, a significant decline from our previous study (89.0%
vs 75.6%; χ2(2) = 20.2, P < .001). Of those making an uninformed choice, 46% had insufficient
knowledge, 19% had not deliberated, and 13% had made a value‐inconsistent decision. Multivar-
iate analysis showed women who were highly educated (OR, 4.33; 95% CI, 1.08‐17.36) or had
had screening in a previous pregnancy (OR, 0.24; 95% CI, 0.90‐0.65) were significantly more likely
to make an informed choice.
Conclusions: The findings highlight the challenges of ensuring informed choice in routine
prenatal care where NIPT is not discussed at multiple points, less time is available for counselling,
and written consent is not required.1 | INTRODUCTION
Non‐invasive prenatal testing (NIPT) using cell‐free DNA in maternal
blood is an advanced screening test, which has been shown to be
highly accurate for Down syndrome with detection rates of over
99% and false positive rates less than 0.1% for singleton pregnancies.1
The test can also be used to screen for trisomies 13 and 18 as well as
sex chromosome aneuploidies; however, detection rates are slightly
lower.1,2 The lower predictive value means that NIPT is not considered
diagnostic and invasive testing is recommended to confirm positive
NIPT results.3,4 Non‐invasive prenatal testing has become widely avail-
able in recent years through the private sector,5 and a number of stud-
ies have been conducted to address implementation within a national
prenatal care setting.6-8 Clinical advantages include improved accuracy
rates in comparison to combined screening,9 reduction in the need for- - - - - - - - - - - - - - - - - - - - - - - - - - -
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by John Wiley & Sons Ltd.invasive tests that carry a small risk of miscarriage,10 early information
about risk status, and the opportunity for early reassurance for low risk
women.11 Nevertheless, a number of disadvantages have been identi-
fied such as the smaller diagnostic yield in comparison to invasive test-
ing with array comparative genomic hybridisation and the potential for
test failures or inconclusive results.12,13
Empirical research has demonstrated that the test is viewed
favourably, withwomen valuing the opportunity to have a safe, accurate
test that can identify cases of Down syndrome that might otherwise be
missed.14-19 However, a number of concerns related to routinisation of
testing have been raised. These include women accepting NIPT without
due thought because of the ease and risk free nature of the proce-
dure,20,21 rapid implementation raising concerns regarding the capacity
of healthcare providers to counsel women appropriately,19,22,23 NIPT
being performed without women realising that they are having a- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cense, which permits use, distribution and reproduction in any medium, provided
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WHAT'S ALREADY KNOWN ABOUT THIS TOPIC?
• Non‐invasive prenatal testing for aneuploidy is a highly
accurate screening test, but concerns exist around
potential routinisation.
• Previous evidence indicated high levels of informed
choice are possible, but this was a tightly controlled
research setting.
WHAT DOES THIS STUDY ADD?
• Non‐invasive prenatal testing can be offered within
routine prenatal care in a way that facilitates high
levels of informed choice.
• However, the decline in rates of informed choice
compared with those in the research setting highlight
the challenges of offering non‐invasive prenatal testing
in routine prenatal care.
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prenatal screening and stigmatisation of those who forego screen-
ing.16,25 A key principle of prenatal testing is the promotion of reproduc-
tive autonomy by providing women and families with information to
assist in pregnancy management with informed choice and informed
consent procedures seen as protecting this principle.21 Consequently,
much discussion has focused on the importance of facilitating informed
choice through provision of balanced pretest information and nondirec-
tive counselling.26-28 In 2016, our research group developed and vali-
dated a measure of informed choice for women offered NIPT, which
was included in a questionnaire assessing women's experience of test-
ing.29 This work formed part of the RAPID evaluation study, which
was designed to investigate implementation of NIPT into the maternity
care pathway in theUKNational Health Service (NHS).30 Using themea-
sure, we found that 89% of women had made an informed choice.29
A key limitation of that informed choice study was that NIPT was
offered within a highly controlled research setting where participants
were given written information at multiple stages and received up to
30 minutes pretest counselling with a specifically trained research mid-
wife who obtained written consent.31 At that time, we acknowledged
that this degree of information and counselling may be challenging to
replicate in a routine clinical setting and recommended further evalua-
tion following NIPT implementation.30 In this paper, we report a fol-
low‐up study designed to assess rates of informed choice among
women offered NIPT following a high risk Down syndrome screening
result (≥1.150) as part of routine NHS care.2 | METHODS
National Health Service Research Ethics Committee approval was
obtained for this study in February 2013 (London—Camden and Isling-
ton 13/LO/0082).2.1 | Participants
Between March 1, 2015, and October 31, 2016, women with a
singleton pregnancy who were identified as high risk (≥1/150)
following Down syndrome screening in antenatal clinics in London and
South East England were offered the option of either NIPT (for T21,
T18, and T13), invasive testing (QF‐PCRon trisomies), or no further test-
ing. Both NIPT and invasive testing were offered at no cost to parents.
The cfDNA sequencing was performed by our NHS service laboratory
(North East Thames Regional Genetics Service) as previously described
for the research trial.6 For women identified as having a Down syn-
drome screening risk ≥1/150, a member of the local maternity care team
(either a fetal medicine midwife or consultant) discussed the options
available including NIPT, invasive testing, or no further investigations.
This follows the model of implementation favoured by the UK National
Screening Committee.32 Prior to the study, maternity care teams were
given group training about NIPT by a member of the RAPID research
team,31 and the NIPT information leaflet developed by the RAPID team
was available to give to patients. Written consent for NIPT was not
required. The care pathways for the delivery of NIPT for the both the
RAPID evaluation study and this study are presented in Figure 1.2.2 | Information and counselling
The health professional training given to local maternity units
highlighted that the information given to women during pretest
counselling should include the following key points: that it is a blood
test and there is no risk of miscarriage associated with the test; that it
tests for Down syndrome, Edward syndrome, and Patau syndrome; that
it detects around 99% of caseswhere the baby has Down syndrome but
that there is a small chance (0.5%‐1%) of a false positive and therefore
invasive testing is recommended to conform a positive result; that the
NIPT result will be ready within 7 to 10 days; that in a small number
of cases, the result is inconclusive or the test fails in which case a repeat
NIPT will be offered; that it is less accurate than invasive testing that is
over 99.9% accurate; that invasive testing carries a small risk of miscar-
riage (0.5%); and that invasive test results will be ready in 3 working
days. The aim of the training sessions was to provide information about
NIPT and answer any questions health professionals had.2.3 | Study procedure
The study was conducted at 6 maternity units to allow recruitment
from a wide range of social and ethnic groups including a large South
Asian population at 2 of the sites. Four of these units had previously
recruited participants into the RAPID evaluation study; two had not.
Between October 2015 and September 2016, women who were
able to read and understand English were invited to take part in this
study on informed choice. A consecutive sample of women were
recruited across each of 6 sites. After the discussion in the clinic,
potential participants were given a Participant Information Sheet
about the study and a paper copy of the questionnaire (Figure S1) to
complete immediately after counselling at the clinic, irrespective of
what prenatal testing option they chose. Participants who were unable
FIGURE 1 Care pathways for the delivery of NIPT [Colour figure can be viewed at wileyonlinelibrary.com]
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ing it home and returning it in the freepost envelope within 1 week.2.4 | Questionnaire
The questionnaire included the measure of informed choice for NIPT,
which comprised questions to assess knowledge, attitude, delibera-
tion,33 andNIPT uptake. The development and validation of themeasure
are described in detail elsewhere.29 An informed choice was defined as
one whereby the participant had good knowledge, had deliberated, and
had a positive attitude and had NIPT or had a negative attitude and
had declined NIPT (classified as value consistency).29 The questionnaire
also included the Decisional Conflict Scale,34 the short form of the State
Trait Anxiety Inventory (STAI‐6),35 questions to explore motivations for
testing, and questions on parity and sociodemographic questions.2.5 | Data analysis
To assess informed choice, knowledge scores, attitude scores, and
deliberation scores were combined with test behaviour. Knowledge
scores were dichotomised as good or poor using a preset cut‐off of
≥9/12. Attitude scores were classified as positive, negative, or neutral
with neutral responders being omitted (approach based on van den
Berg et al).29 Deliberation scores were dichotomised as either deliber-
ated or nondeliberated. For the purposes of the informed choice calcu-
lation, we excluded women who had declined NIPT but had opted for
invasive testing. This was because whilst many of them had a positive
attitude towards NIPT, they had declined the test and opted for inva-
sive testing which, according to the definition of the measure, would
have categorised them as having made an uninformed choice. How-
ever, a limitation of the measure is that it is unable to account for these
more complex situations whereby a positive attitude towards NIPT isnot behaviourally implemented, not because the decision is uninformed
but for practical reasons such as not wanting to wait 7 to 10 days for
the test result or the indication for trisomy being so strong that invasive
testing was considered most appropriate. A similar approach was taken
by van Schendel et al in their assessment of informed choice.36
The Decisional Conflict Scale score was calculated as directed by
O'Connor34 with participants scoring ≥37.5 categorised as having deci-
sional conflict. The 6‐item State Trait Anxiety Index was scored accord-
ing to the authors' instructions35 with scores of ≥50 indicating elevated
state anxiety. Descriptive analysis was conducted on single items.
Regression analysis was conducted to determine which independent
variables were significant predictors of informed choice. Religion and
ethnicity were collapsed into binary variables to strengthen the analysis.
A Mann‐Whitney test was used to determine differences in decisional
conflict and anxiety between women making informed and uninformed
decisions. A chi‐square test was used to compare rates of informed
choice between the RAPID evaluation study and this study. Missing data
on the knowledge scale were treated as incorrect answers. Question-
naires with ≥50% missing data were removed from the analysis. Where
there was <50% missing data, missing values were replaced by imputing
the mean. Analysis was performed using SPSS 22 (IBM, Chicago, Illinois).3 | RESULTS
3.1 | Sample characteristics
A total of 220 of 247 women invited to take part in the study com-
pleted Q1 (89% response rate). Two questionnaires were removed
due to ≥50%missing data (N = 218). Participant characteristics are pre-
sented in Table 1. The mean age was 35.7 years (range, 23‐47). One
participant had opted for no further testing, and 10 had chosen
TABLE 1 Participant characteristics
Participant Characteristics
N = 218
n (%)
Maternal age—mean; range (missing 10) 35.7 y; 23‐47
Educational level (missing 7)
No qualification 5 (2.4)
GCSE or O level 22 (10.4)
GCE, A level or similar 15 (7.1)
Vocational (BTEC/NVQ/diploma) 30 (14.2)
Degree level or above 139 (65.9)
Ethnicity (missing 15)
White or White British 145 (71.4)
Asian or Asian British 21 (10.3)
Black or Black British 19 (8.7)
Other ethnic group 16 (7.9)
Mixed 2 (0.9)
Religious faith (missing 9)
Yes 120 (56.6)
No 92 (43.4)
Which faith (missing 0)
Christian 88 (73.3)
Muslim 22 (18.3)
Jewish 3 (2.5)
Other 3 (2.5)
Sikh 2 (1.7)
Hindu 1 (0.8)
Buddhist 1 (0.8)
Religiosity (missing 25)
Very 22 (23.2)
Somewhat 57 (60.0)
Not at all 16 (16.8)
Further testing (missing 0)
NIPT 207 (94.9)
Invasive testing 10 (4.6)
No further testing 1 (0.5)
Children (missing 5)
Yes 133 (62.4)
No 80 (37.6)
DSS in previous pregnancya
Yes 90 (68.2)
No 36 (27.3)
Not sure 6 (4.5)
Have a child with DS (missing 5)
Yes 3 (2.3)
No 125 (97.7)
Know anyone who has a child with DS (missing 17)
Yes 50 (24.9)
No 151 (75.1)
Abbreviations: DSS = Down syndrome screening, DS = Down syndrome;
NIPT, non‐invasive prenatal testing.
Note: Not all % add up to 100 due to rounding. Not all participants
answered all questions, and therefore, there are some discrepancies with
total numbers.
aIt is not possible to work out “missing” here as some may have had a pre-
vious pregnancy that did not result in having a child presently.
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nificantly between women who opted for invasive testing vs NIPT
(mean, 58.4 vs 73.8, respectively; F = 1.10, P = .30).3.2 | Informed choice
Of the total sample (N = 218), 84.9% had good knowledge (n = 185);
81.7% had a positive attitude (n = 178), 12.8% (n = 28) had a negative
attitude, and 5.5% had a neutral attitude (n = 12); and 93.1% had delib-
erated (n = 203). Of the 10 women who opted for invasive testing over
NIPT, 6 had a positive attitude towards NIPT, 3 had a negative atti-
tude, and 1 had a neutral attitude.
For the informed choice calculation, 11 questionnaires were
excluded because the participant had a neutral attitude towards NIPT,
9 questionnaires were removed because the participant had opted for
invasive testing, and 1 questionnaire was removed because the partic-
ipant had a neutral attitude and had opted for invasive testing. The
informed choice analysis therefore included 197 questionnaires and
showed that 75.6% of women (n = 149) made an informed choice
about NIPT; 88.8% (n = 175) had good knowledge, 95.4% (n = 188)
had deliberated, and 87.3% (n = 172) made a decision that was value
consistent. Of those participants that made an uninformed choice
(24.4%, n = 48), 45.8% (n = 22) had insufficient knowledge, 18.8%
(n = 9) had not deliberated, and 13.2% (n = 26) had made a value‐incon-
sistent decision (Table 2).
Univariate analysis showed thatwomenmaking an informed choice
were significantly more likely to be highly educated (OR, 3.37; 95% CI,
1.26‐8.97; P < .05), have no religious affiliation (OR, 0.43; 95% CI,
0.21‐0.88; P < .05), be White ethnicity (OR, 0.37; 95% CI, 0.19‐0.73;
P < .05), and had DS screening in a previous pregnancy (OR, 0.27; 95%
CI, 0.11‐0.64; P < .05). Multivariate analysis showed that women who
were highly educated (OR, 4.33; 95% CI, 1.08‐17.36; P < .05) or had
DS screening in a previous pregnancy (OR, 0.24; 95% CI, 0.90‐0.65;
P < .05) were significantly more likely to make an informed choiceTABLE 2 Types of informed and uninformed choices
Knowledge Deliberation Attitude Uptake n (%)
Informed choice Good Yes Positive Yes 149 (75.6)
Good Yes Negative No 0 (0)
Uninformed
choice
Good Yes Negative Yes 17 (8.6)
Poor Yes Positive Yes 16 (8.1)
Good No Positive Yes 6 (3.0)
Poor Yes Negative Yes 6 (3.0)
Good No Negative Yes 2 (1.0)
Good Yes Positive No 1 (0.5)
Poor No Positive Yes 1 (0.5)
Good Yes Positive No 0 (0)
Good No Negative No 0 (0)
Good No Positive No 0 (0)
Good No Negative Yes 0 (0)
Poor Yes Positive No 0 (0)
Poor No Positive No 0 (0)
Poor No Negative Yes 0 (0)
TABLE 3 Univariate and multiple logistic regression looking at factors associated with making an informed choice
Univariate Logistic Regression
Informed Choice (N = 197)
Multiple Logistic Regression
Informed Choice (N = 172)
Variable Made IC OR (95%CI) OR (95% CI)
Age
≤34 47 (69.1%) 1 1
35‐39 63 (79.7%) 1.76 (0.83‐3.73) 1.48 (0.62‐3.53)
≥40 36 (83.7%) 2.30 (0.88‐6.00) 1.94 (0.64‐5.82)
Level of education
GCSE or lower 11 (55.0%) 1 1
GCE or vocational 28 (73.7%) 2.29 (0.73‐7.16) 2.99 (0.86‐10.35)
Degree or above 107 (80.5%) 3.37 (1.26‐8.97)* 4.33 (1.08‐17.36)*
Ethnicity
White 110 (82.1%) 1 1
Other 39 (62.9%) 0.37 (0.19‐0.73) * 0.53 (0.22‐1.25)
Religion
No 70 (84.3%) 1 1
Yes 76 (69.7%) 0.43 (0.21‐0.88)* 0.57 (0.24‐1.32)
Had DS screening previously
Yes 67 (80.7%) 1 1
No or not sure 18 (52.9%) 0.27 (0.11‐0.64)* 0.24 (0.90‐0.65)*
Not applicable 61 (82.4%) 1.12 (0.50‐2.52) 0.99 (0.37‐2.63)
Has or knows a child with DS
Yes 38 (80.9%) 1 1
No 100 (74.6%) 0.70 (0.31‐1.59) 0.79 (0.34‐2.03)
Abbreviation: DS, Down syndrome.
*P < .05.
**P < .001.
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and the subscales of informed choice further. Analysis indicated that
there was a positive association between higher education level and
higher knowledge score (H(2) = 11.04, P = .004), whereas education
was not associated with attitude or deliberation scores.3.3 | Comparison with RAPID evaluation study
There was a significant decline in the rate of informed choice in this
study when compared to the RAPID evaluation study (89.0% vs
75.6%; χ2(2) = 20.2, P < .001). Knowledge scores were significantly
lower (95.4% vs 88.8%; χ2(2) = 10.4, P = .001), and fewer participants
had a positive attitude towards NIPT (97.7% vs 87.3%; χ2(2) = 32.0,
P < .001). When comparing the high risk women in this study with high
risk women from the RAPID evaluation study, rates of informed choice
were still significantly lower (93.5% vs 76.5%; χ2(2) = 19.8, P < .001),
there were still significantly fewer women in this study with a positive
attitude (97.4% vs 87.3%; χ2(2) = 11.5, P = .001), and fewer women
judged to have good knowledge (96.7% vs 88.8%; χ2(2) = 7.5,
P = .06); however, this was not significant. Deliberation scores were
not significantly different when comparing women in this study with
the total RAPID evaluation study sample nor high risk women only
(93.9% vs 95.4%, χ2(2) = 0.6, P = .43 and 97.4% vs 95.4%, χ2(2) = 0.9,
P = .343).3.4 | Decisional conflict and state‐trait anxiety
Decisional conflict occurred in 6.6% (n = 13) of cases. Women who
made an uninformed decision were significantly more likely to experi-
ence decisional conflict than women who made an informed decision
(Mdn, 19.53 vs 1.56, respectively; U = 1980, P < .001). Anxiety was
found to be elevated in 62.6% (n = 119) of cases. Anxiety scores were
not found to have a significant impact on informed decision‐making
(Mdn 50.00 uninformed choice vs Mdn 53.3 informed choice;
U = 2866, P = .217). There were no significant differences between
the women in this study and the high risk women in the RAPID evalu-
ation study when we looked at decisional conflict (3.0% vs 6.6%;
χ2(2) = 2.4, P = .12) and anxiety (54.5% vs 60.4%; χ2(2) = 1.2, P = .261).3.5 | Motivations for accepting or declining NIPT
Of those women who opted for NIPT, the most frequently cited reason
was “for reassurance that the baby doesn't have Down syndrome”
(28.1%) followed by “to help me make a decision about whether or
not continue with the pregnancy” (21.9%). Of those women who chose
invasive testing over NIPT, the most frequently cited reason was
because they would “get the results more quickly” (46.6%). Only one
participant declined any further testing, the reason being “I would
never terminate an affected pregnancy so there would be no point
taking the test” (Table 4).
TABLE 4 Motivations for accepting or declining non‐invasive prenatal testing (NIPT)
Motivations for choosing NIPT Total N = 338
For reassurance that my baby doesn't have Down syndrome n = 95 (28.1%)
To help me make a decision about whether or not to continue with the pregnancy n = 74 (21.9%)
I would want as much information about the baby as possible n = 55 (16.3%)
So I can plan and prepare for the birth of a baby with Down's syndrome n = 35 (10.4%)
Because there is no risk to the baby n = 21 (6.2%)
To avoid having a child with Down's syndrome n = 12 (3.6%)
Because it was offered to me as part of my antenatal care n = 10 (1.2%)
Other n = 3 (0.9%)
Because my partner or family would want me to n = 1 (0.3%)
Motivations for choosing invasive testing Total N = 15
I will get the results more quickly n = 7 (46.6%)
It is more accurate than NIPT n = 4 (26.7%)
The indication for Down syndrome or another chromosomal abnormality was so strong that I chose invasive testing n = 4 (26.7%)
Other n = 0 (0.0%)
Note: N = total number of responses. Participants were allowed to select up to 2 responses for the motivations to accept NIPT.
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Many of the ethical concerns raised about NIPT relate to routinisation
of testing and erosion of informed choice.20,21,23,37 Our study indicates
that even when NIPT is offered as part of routine clinical practice, it is
possible to achieve high rates of informed decision‐making amongst
women who choose to have NIPT. Most women in this study had good
knowledge about NIPT, had deliberated, and had positive attitudes
towards NIPT. These findings concur with our previous work29 and
other recently published studies assessing informed choice in a
research setting such as the study published in the Netherlands where
78% of women were found to have made an informed choice about
NIPT using a similar measure assessing knowledge, attitudes, and
uptake,36 as well as research examining patient understanding of
NIPT.38,39 Nevertheless, the rate of informed choice was found to be
significantly lower in this study compared to our previous study.29 This
is perhaps not surprising given that in our previous study, NIPT was
being offered within a highly controlled research environment with
additional time provided for pretest counselling, clear signposting of
NIPT at multiple time points, and women were asked to sign a consent
form. The findings from our current study might be considered to give
a more realistic representation of informed choice amongst women
who are high risk and making decisions about NIPT. The finding that
rates of informed choice were lower once NIPT was offered by the
clinical team, without additional input from researchers or the need
to sign a consent form, highlights the challenges of ensuring high qual-
ity pretest counselling in the context of routine prenatal care.
Our data, along with others,36,38,39 indicate that particular atten-
tion should be given to women with lower education and/or health lit-
eracy levels as they are less likely to have sufficient knowledge to
make informed decisions about NIPT and underscores the importance
of developing novel tools to support this group of women. The devel-
opment of interactive decision aids to complement written and verbal
information might be one potential solution. Interactive computer aids
have been found to improve patient knowledge in a number of studies
focused on prenatal testing.40,41 Alternatively, an informational filmcould be developed and piloted. This approach was found to enhance
knowledge and informed decision‐making around Down syndrome
screening in a study conducted in Sweden.42
As has been identified in other studies looking at informed decision‐
making in pregnancy,36,43 decisional certainty was found to be positively
associated with an informed decision, supporting the use of the Deci-
sional Conflict Scale as a good indicator of informed decision‐making
and underscoring that informed choice is associated with better psycho-
logical outcomes.44 Decisional conflict, the extent to which a person
feels uncertain, unclear about personal values, and unsupported in deci-
sion‐making, has been associated with decisional regret,45which could
potentially have serious consequences for women making important
decisions in pregnancy. Further research to address causes of decisional
conflict and ways in which these women may benefit from additional
decision support to reduce their uncertainty would be valuable.
A number of recently published papers have demonstrated that
patients may underestimate the limitations of NIPT, in particular the
potential for a false positive or inconclusive result.38,39 These concerns
are supported to some extent by our results as the question answered
incorrectlymost frequently on the knowledge scale related to the poten-
tial for an inconclusive NIPT result (Table S1). Inconclusive NIPT results
may occur due to low fetal fraction or sequencing failures and have been
reported as occurring as frequently as 6% of cases.12 Recent publica-
tions also suggest that patients who receive an inconclusive NIPT result
may be at increased risk of aneuploidy.9 These findings highlight the
importance of pretest counselling in addressing any misconceptions
about the test and ensuring patients understand the potential for an
inconclusive result to reduce the chance of decisional regret later on.
In this study, NIPTwas offered as a contingent test towomenwith a
high risk result from the combined screening test, in line with the model
the UK National Screening Committee plan for NHS implementation in
2018.32 However, NIPT is increasingly being made available to the gen-
eral obstetric population in the UK through private practice as a first line
test. The importance of a multistep deliberative process facilitated
through contingent testing has been identified previously in studies of
women's experience of being offered NIPT.15 However, as the cost of
1136 LEWIS ET AL.sequencing falls and NIPT testing gets cheaper, there is the potential to
use it as a first line screening test. Given that rates of informed choice
fell when offered in routine clinical practice, we will need to carefully
re‐evaluate this in settings where NIPT is offered as a first line test.
We used a measure of informed choice that has previously been
validated amongst women considering NIPT as a second screening test
and had a high response rate. A strength of this measure is that it is
sensitive enough to pick up differences between different settings.
However, a limitation relates to the attitude scale not being sophisti-
cated enough to pick up informed decision‐making in certain circum-
stances, such as where a positive attitude is not behaviourally
implemented because an alternative testing option is preferred. By
excluding women who chose invasive testing from the informed choice
calculation, we may have artificially increased the percentage of
women making informed choices. Further development of the attitude
scale to address this limitation is required.
The main limitation of this study is that we did not receive any
questionnaires from NIPT decliners. We therefore cannot comment
on whether they had made an informed choice to decline NIPT. This
was also the case in our previous study, where only 13 of 585 partici-
pants had declined further tests. In this study, training was available to
the local maternity care teams, and the intention was to include all
health professionals who would speak to women about NIPT, including
the midwives who would discuss the test at booking and those who
would offer NIPT and give results. We do not, however, know what
cascade training was done with health professionals who did not
attend training. However, this does reflect reality of how a busy mater-
nity department works. Training was provided by the RAPID research
team, and 4 of the 6 units had participated in the RAPID evaluation
study, which could be perceived as an inherent bias in the study. Our
sample predominantly comprised older, well‐educated women; how-
ever, this probably reflects the fact that older women are more likely
to be at increased risk and be highly educated as they have delayed
child bearing for educational or vocational reasons. Finally, in our
study, we found that 62.6% of women had elevated anxiety scores at
the time of testing. This finding is in line with other studies looking
at anxiety in women identified as high risk through screening.46 Never-
theless, the absence of a baseline anxiety assessment is a limitation as
we are unable to determine whether these women were anxious prior
to testing or whether anxiety increased as a result of screening.5 | CONCLUSION
Non‐invasive prenatal testing is set to become part of routine care in
the UKNHS imminently. Maintaining high levels of informed choice will
be very dependent on effective training of health professionals to
ensure they can provide up‐to‐date unbiased information and also have
the confidence and skills to support parents to discuss prenatal testing
options in a way that reflects their patients' values and beliefs. Recent
guidelines emphasise the importance of having pretest face‐to‐face
conversations with patients about their values regarding termination
and pregnancy planning to help direct and personalise counselling as
well as ensuring patients are clear that screening and testing are
optional.47 Current research shows it is possible to achieve high levelsof informed decision‐making for NIPT, but given the possibility of NIPT
as a first line screening test continued research in this area is important.
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